Scholarlink

<p>Medulloblastoma (MB) is the most common malignant pediatric brain tumor. The increasing emphasis in genomic research within recent decades has shined a spotlight on the genomic and epigenetic landscape of this disease. Through methylome and transcriptome data from large MB patient cohorts, four discrete molecular subgroups and their respective subtypes have been identified, each with differing molecular and clinical characteristics. In this review, we outline recent discoveries concerning MB subgroups and subtypes, and how they have informed new epigenetic, radiation, and immunological therapeutic approaches. Although these discoveries have guided the de-escalation of low-risk molecular subgroups, to date, no subgroup-specific therapeutic strategies have been implemented in the clinic. Currently, a paucity of tractable molecular alterations and preclinical models has been a major barrier for the development of meaningful MB therapies. A strong focus on elucidating these gaps in knowledge will allow for the development of tailored therapies for high-risk MB and metastatic recurrence.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

From developmental origins to relapse: molecular and therapeutic insights in medulloblastoma

  • 期刊论文

  • 发表日期：

    2026年7月7日

查看全文
  • Noah Tourigny,
  • Carolina Fernandes da Silva,
  • Vijay Ramaswamy

摘要

Medulloblastoma (MB) is the most common malignant pediatric brain tumor. The increasing emphasis in genomic research within recent decades has shined a spotlight on the genomic and epigenetic landscape of this disease. Through methylome and transcriptome data from large MB patient cohorts, four discrete molecular subgroups and their respective subtypes have been identified, each with differing molecular and clinical characteristics. In this review, we outline recent discoveries concerning MB subgroups and subtypes, and how they have informed new epigenetic, radiation, and immunological therapeutic approaches. Although these discoveries have guided the de-escalation of low-risk molecular subgroups, to date, no subgroup-specific therapeutic strategies have been implemented in the clinic. Currently, a paucity of tractable molecular alterations and preclinical models has been a major barrier for the development of meaningful MB therapies. A strong focus on elucidating these gaps in knowledge will allow for the development of tailored therapies for high-risk MB and metastatic recurrence.